BR112014011028A2 - molécula de ligação isolada ou fragmento de ligação de antígeno da mesma, anticorpo biespecífico, molécula de polinucleotídeo isolada, composição, método para a prevenção ou tratamento de uma infecção por pseudomonas em um indivíduo, e, kit - Google Patents

molécula de ligação isolada ou fragmento de ligação de antígeno da mesma, anticorpo biespecífico, molécula de polinucleotídeo isolada, composição, método para a prevenção ou tratamento de uma infecção por pseudomonas em um indivíduo, e, kit

Info

Publication number
BR112014011028A2
BR112014011028A2 BR112014011028A BR112014011028A BR112014011028A2 BR 112014011028 A2 BR112014011028 A2 BR 112014011028A2 BR 112014011028 A BR112014011028 A BR 112014011028A BR 112014011028 A BR112014011028 A BR 112014011028A BR 112014011028 A2 BR112014011028 A2 BR 112014011028A2
Authority
BR
Brazil
Prior art keywords
isolated
molecule
kit
treating
preventing
Prior art date
Application number
BR112014011028A
Other languages
English (en)
Other versions
BR112014011028B1 (pt
Inventor
Digiandomenico Antonio
Bezabeh Binyam
Sellman Bret
Gao Changshou
Stover Charles
Gao Cuihua
Rainey Godfrey
Peng Li
Damschroder Melissa
Tomich Mladen
Dimasi Nazzareno
Chowdhury Partha
Warrener Paul
Minter Ralph
Varkey Reena
Fleming Ryan
Guillard Sandrine
Rust Steven
Venkatraman Vignesh
Original Assignee
Medimmune Ltd
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd, Medimmune Llc filed Critical Medimmune Ltd
Publication of BR112014011028A2 publication Critical patent/BR112014011028A2/pt
Publication of BR112014011028B1 publication Critical patent/BR112014011028B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
BR112014011028-0A 2011-11-07 2012-11-06 anticorpo biespecífico, composição, e, uso da composição BR112014011028B1 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161556645P 2011-11-07 2011-11-07
US61/556,645 2011-11-07
US201261625299P 2012-04-17 2012-04-17
US61/625,299 2012-04-17
US201261697585P 2012-09-06 2012-09-06
US61/697,585 2012-09-06
PCT/US2012/063722 WO2013070615A1 (en) 2011-11-07 2012-11-06 Combination therapies using anti- pseudomonas psl and pcrv binding molecules

Publications (2)

Publication Number Publication Date
BR112014011028A2 true BR112014011028A2 (pt) 2017-05-02
BR112014011028B1 BR112014011028B1 (pt) 2021-03-02

Family

ID=48290482

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014011028-0A BR112014011028B1 (pt) 2011-11-07 2012-11-06 anticorpo biespecífico, composição, e, uso da composição

Country Status (22)

Country Link
US (3) US10597439B2 (pt)
EP (1) EP2776065B1 (pt)
JP (1) JP6182152B2 (pt)
KR (1) KR102184343B1 (pt)
CN (1) CN104136042B (pt)
AU (3) AU2012336028A1 (pt)
BR (1) BR112014011028B1 (pt)
CA (2) CA2854817C (pt)
CY (1) CY1123552T1 (pt)
DK (1) DK2776065T3 (pt)
ES (1) ES2859323T3 (pt)
HK (1) HK1201453A1 (pt)
HR (1) HRP20201370T1 (pt)
HU (1) HUE050985T2 (pt)
LT (1) LT2776065T (pt)
MX (1) MX2014005566A (pt)
PL (1) PL2776065T3 (pt)
PT (1) PT2776065T (pt)
RS (1) RS60920B1 (pt)
RU (1) RU2687588C2 (pt)
SI (1) SI2776065T1 (pt)
WO (1) WO2013070615A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2718320T3 (en) 2011-06-10 2018-03-26 Medimmune Ltd ANTI-PSEUDOMONAS-PSL BINDING MOLECULES AND APPLICATIONS THEREOF
ES2859323T3 (es) 2011-11-07 2021-10-01 Medimmune Ltd Terapias de combinación que usan moléculas de unión anti-Psl y PcrV de Pseudomonas
KR20140132748A (ko) * 2012-03-02 2014-11-18 아블린쓰 엔.브이. 슈도모나스 애루기노사 pcrv 결합 단일 가변 도메인 항체
MX2015005719A (es) * 2012-11-06 2016-01-12 Medimmune Llc Terapias de combinacion que usan moleculas de union anti-psl y pcrv de pseudomonas.
JP2016524606A (ja) * 2013-05-14 2016-08-18 メディミューン，エルエルシー 緑膿菌（Ｐｓｅｕｄｏｍｏｎａｓａｅｒｕｇｉｎｏｓａ）のＰｓｌエキソ多糖の合成オリゴ糖サブユニットおよびその使用
EP3139950A4 (en) * 2014-05-05 2017-12-20 Medimmune, LLC Multi-specific anti-pseudomonas psl and pcrv binding molecules and uses thereof
TWI719938B (zh) * 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
KR20180020142A (ko) * 2015-05-01 2018-02-27 인히브릭스 엘피 Iii형 분비계 표적화 분자
BR112018003252A2 (pt) * 2015-08-24 2018-09-25 Medimmune Llc polipeptídeos mrka, anticorpos, e usos dos mesmos
SG10201913100WA (en) 2015-11-30 2020-03-30 Medimmune Ltd Method for preventing or treating nosocomial pneumonia
SG11201809778TA (en) * 2016-05-05 2018-12-28 Univ Pennsylvania Dna antibody constructs for use against pseudomonas aeruginosa
CA3140075A1 (en) 2019-06-11 2020-12-17 Regeneron Pharmaceuticals, Inc. Anti-pcrv antibodies that bind pcrv, compositions comprising anti-pcrv antibodies, and methods of use thereof
AU2020311511A1 (en) * 2019-07-09 2022-02-03 Beijing Solobio Genetechnology Co., Ltd. Antibodies specifically recognizing Pseudomonas PcrV and uses thereof
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
CN114072145A (zh) * 2020-06-01 2022-02-18 舒泰神（北京）生物制药股份有限公司 特异性识别假单胞菌pcrv的抗体及其用途
US20230295279A1 (en) * 2020-08-07 2023-09-21 Beijing Solobio Genetechnology Co., Ltd. Antibodies Specifically Recognizing Pseudomonas Psl and Uses Thereof
FR3114970B1 (fr) * 2020-10-08 2023-06-30 Univ Tours Combinaison d’anticorps inhalés avec des agents immunomodulateurs pour le traitement ou la prévention d’inféctions respiratoires
US20240002482A1 (en) * 2020-11-18 2024-01-04 Beijing Solobio Genetechnology Co., Ltd. Combinations of Antibodies and Bispecific Antibodies Comprising Antigen-Binding Specifically Recognizing Pseudomonas PcrV and Psl
WO2023141611A2 (en) * 2022-01-21 2023-07-27 Lyvgen Biopharma Holdings Limited Multi-specific antibodies in uses thereof in avidity receptor crosslinking and immune modulation
WO2024003103A1 (en) 2022-06-29 2024-01-04 Astrazeneca Ab Anti-pcrv and psl bispecific antibodies for treatment of bronchiectasis

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
WO1986005396A1 (en) 1985-03-11 1986-09-25 Teijin Limited E87ag antigen of pseudomonas aeruginosa, monoclonal antibody against it, and hybridoma
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
WO1991010741A1 (en) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
EP0564531B1 (en) 1990-12-03 1998-03-25 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US5525491A (en) 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
EP0580737B1 (en) 1991-04-10 2004-06-16 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US6420140B1 (en) 1996-10-11 2002-07-16 Abgenix, Inc. Production of multimeric protein by cell fusion method
WO1999004705A1 (en) 1997-07-25 1999-02-04 Tsui Ban C H Devices, systems and methods for determining proper placement of epidural catheters
JP4169478B2 (ja) 1998-04-21 2008-10-22 マイクロメット アーゲー Ｃｄ１９×ｃｄ３特異的ポリペプチドおよびその使用
AU3580800A (en) 1998-11-25 2000-06-26 Mcw Research Foundation, Inc. Method of and compositions for immunization with the (pseudomonas) v antigen
DE60126130T2 (de) 2000-11-17 2007-10-18 The University Of Rochester In-vitro verfahren zur herstellung und identifizierung von immunglobulin moleküle in eukaryotischen zellen
ES2649037T3 (es) 2000-12-12 2018-01-09 Medimmune, Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
US7494653B2 (en) 2001-01-26 2009-02-24 Mcw Research Foundation, Inc. Method and compositions for immunization with the Pseudomonas V antigen
WO2002096948A2 (en) 2001-01-29 2002-12-05 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
US20020146753A1 (en) 2001-04-06 2002-10-10 Henrik Ditzel Autoantibodies to glucose-6-phosphate isomerase and their participation in autoimmune disease
US7119172B2 (en) 2001-05-21 2006-10-10 The Brigham And Women's Hospital, Inc. P. aeruginosa mucoid exopolysaccharide specific binding peptides
US20030232387A1 (en) * 2002-06-14 2003-12-18 Millennium Pharmaceuticals, Inc. Antibodies that bind alphaE integrin
US20090215992A1 (en) 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
AU2006283532B2 (en) 2005-08-19 2012-04-26 Abbvie Inc. Dual variable domain immunoglobin and uses thereof
US7790862B2 (en) * 2006-06-13 2010-09-07 Zymogenetics, Inc. IL-17 and IL-23 antagonists and methods of using the same
JP2008133206A (ja) * 2006-11-28 2008-06-12 Yokohama City Univ 緑膿菌に対して感染防御能を誘導できる医薬組成物
US7553936B2 (en) 2006-12-04 2009-06-30 The United States of America as represented by Secretary Department of Health and Human Services Anti-TREM-like transcript-1 (TLT-1) antibodies and compositions
WO2008074840A2 (en) 2006-12-19 2008-06-26 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
EA201000903A1 (ru) * 2007-11-30 2011-02-28 Калобиос Фармасьютикалс, Инк. Антитела к pcrv-антигену pseudomonas aeruginosa
ES2426093T3 (es) * 2008-01-10 2013-10-21 Shionogi & Co., Ltd. Anticuerpo dirigido contra PcrV
US20110033378A1 (en) 2008-01-18 2011-02-10 Medlmmune, Llc. Cysteine Engineered Antibodies For Site-Specific Conjugation
CN102301235B (zh) 2008-11-28 2014-11-19 Abbvie公司 稳定的抗体组合物和用于稳定其的方法
JO3672B1 (ar) * 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
EP2679515B1 (en) * 2008-12-31 2014-07-02 W.L. Gore & Associates GmbH Venting device
US20100272736A1 (en) * 2009-02-04 2010-10-28 Kalobios Pharmaceuticals, Inc. Combination antibiotic and antibody therapy for the treatment of pseudomonas aeruginosa infection
AU2010222150B2 (en) * 2009-03-11 2015-07-16 Shionogi & Co. Ltd. Humanized PcrV antibody having anti-Pseudomonal activity
WO2010107778A1 (en) * 2009-03-18 2010-09-23 Wake Forest University Health Sciences Flagellin fusion proteins and use thereof to induce immune responses against pseudomonas aeruginosa
US8734796B2 (en) 2009-03-20 2014-05-27 Amgen Inc. Carrier immunoglobulins
WO2010115606A1 (en) 2009-04-09 2010-10-14 Kenta Biotech Ag Human monoclonal antibody specific for lipopolysaccarides (lps) of serotype iats 01 of pseudomonas aeruginosa
US20120213705A1 (en) 2009-06-22 2012-08-23 Medimmune, Llc ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
WO2011087799A1 (en) 2009-12-22 2011-07-21 Kalobios Pharmaceuticals, Inc. A method of treating a staphylococcus infection in a patient having a low-level pathogenic pseudomonas aeruginosa infection
PT2673373T (pt) * 2011-02-08 2018-12-05 Medimmune Llc Anticorpos que ligam especificamente a toxina alfa de staphylococcus aureus e métodos de utilização
WO2012145626A1 (en) 2011-04-22 2012-10-26 Ancora Pharmaceuticals Inc. Synthetic oligosaccharides for staphylococcus vaccine
DK2718320T3 (en) 2011-06-10 2018-03-26 Medimmune Ltd ANTI-PSEUDOMONAS-PSL BINDING MOLECULES AND APPLICATIONS THEREOF
ES2859323T3 (es) * 2011-11-07 2021-10-01 Medimmune Ltd Terapias de combinación que usan moléculas de unión anti-Psl y PcrV de Pseudomonas
JP2014533249A (ja) * 2011-11-07 2014-12-11 メディミューン，エルエルシー 多重特異性を持つ多価結合タンパク質およびその使用
KR20140132748A (ko) * 2012-03-02 2014-11-18 아블린쓰 엔.브이. 슈도모나스 애루기노사 pcrv 결합 단일 가변 도메인 항체
KR20210083389A (ko) 2012-11-06 2021-07-06 메디뮨 엘엘씨 에스.아우레우스 연관 질병의 치료 방법
MX2015005719A (es) * 2012-11-06 2016-01-12 Medimmune Llc Terapias de combinacion que usan moleculas de union anti-psl y pcrv de pseudomonas.
SG11201503232TA (en) * 2012-11-06 2015-05-28 Medimmune Llc Antibodies to s. aureus surface determinants
JP2016524606A (ja) 2013-05-14 2016-08-18 メディミューン，エルエルシー 緑膿菌（Ｐｓｅｕｄｏｍｏｎａｓａｅｒｕｇｉｎｏｓａ）のＰｓｌエキソ多糖の合成オリゴ糖サブユニットおよびその使用
EP3139950A4 (en) * 2014-05-05 2017-12-20 Medimmune, LLC Multi-specific anti-pseudomonas psl and pcrv binding molecules and uses thereof
TWI719938B (zh) * 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
SG10201913100WA (en) * 2015-11-30 2020-03-30 Medimmune Ltd Method for preventing or treating nosocomial pneumonia
SG11201809778TA (en) * 2016-05-05 2018-12-28 Univ Pennsylvania Dna antibody constructs for use against pseudomonas aeruginosa
CA3140075A1 (en) * 2019-06-11 2020-12-17 Regeneron Pharmaceuticals, Inc. Anti-pcrv antibodies that bind pcrv, compositions comprising anti-pcrv antibodies, and methods of use thereof

Also Published As

Publication number Publication date
EP2776065A4 (en) 2016-03-02
RU2687588C2 (ru) 2019-05-15
EP2776065A1 (en) 2014-09-17
CY1123552T1 (el) 2022-03-24
CN104136042A (zh) 2014-11-05
NZ722379A (en) 2019-12-20
HK1201453A1 (en) 2015-09-04
US20220177554A1 (en) 2022-06-09
US10597439B2 (en) 2020-03-24
AU2017219081A1 (en) 2017-09-14
AU2017219081B9 (en) 2019-07-04
NZ624072A (en) 2016-09-30
JP2015504421A (ja) 2015-02-12
WO2013070615A8 (en) 2013-06-20
CA2854817C (en) 2022-08-16
PT2776065T (pt) 2020-09-25
KR20140091736A (ko) 2014-07-22
AU2019226205A1 (en) 2019-09-26
ES2859323T3 (es) 2021-10-01
AU2012336028A1 (en) 2014-06-26
AU2017219081B2 (en) 2019-06-06
CA2854817A1 (en) 2013-05-16
RS60920B1 (sr) 2020-11-30
HRP20201370T1 (hr) 2020-11-27
DK2776065T3 (da) 2020-10-12
BR112014011028B1 (pt) 2021-03-02
US20200317757A1 (en) 2020-10-08
US11203633B2 (en) 2021-12-21
RU2014122990A (ru) 2015-12-20
WO2013070615A1 (en) 2013-05-16
HUE050985T2 (hu) 2021-01-28
JP6182152B2 (ja) 2017-08-16
MX2014005566A (es) 2014-10-14
US20150023966A1 (en) 2015-01-22
CN104136042B (zh) 2017-08-18
EP2776065B1 (en) 2020-08-05
SI2776065T1 (sl) 2020-10-30
KR102184343B1 (ko) 2020-11-30
LT2776065T (lt) 2020-10-12
PL2776065T3 (pl) 2020-12-14
CA3161431A1 (en) 2013-05-16

Similar Documents

Publication Publication Date Title
BR112014011028A2 (pt) molécula de ligação isolada ou fragmento de ligação de antígeno da mesma, anticorpo biespecífico, molécula de polinucleotídeo isolada, composição, método para a prevenção ou tratamento de uma infecção por pseudomonas em um indivíduo, e, kit
BR112014002618A2 (pt) anticorpo ou um fragmento do mesmo, que tem reatividade imunológica com uma proteína caprin-1, composição farmaceutica e combinação farmacêutica para tratamento e/ou prevenção de câncer, dna e método para tratamento e/ou prevenção de cãncer
BR112012018947A8 (pt) composição farmacêutica para o tratamento e/ou prevenção de um câncer, anticorpo, combinação farmacêutica e método para o tratamento e/ou prevenção de um câncer
BR112012003809A2 (pt) anticorpa monoclonal isolado ou porção de ligação a antígeno do mesmo, composição e, método para tratar câncer em um indivíduo.
BR112014002614A2 (pt) anticorpo ou um fragmento do mesmo, que tem reatividade imunológica com uma proteína caprin-1, composição farmacêutica e combinação farmacêutica para tratamento e/ou prevenção de câncer, dna e método para tratamento e/ou prevenção de câncer
BR112012018951A2 (pt) composição farmacêutica, combinação farmacêutica e método para o tratamento e\ou prevenção de um câncer e anticorpo
BR112014002621A2 (pt) anticorpo, composição farmacêutica, combinação farmacêutica, dna e método de tratamento
BR112014000263A2 (pt) anticorpo isolado ou fragmento de ligação de antígeno do mesmo, molécula de ácido nucleico, e, composição farmacêutica
BRPI0817664A2 (pt) Nanopartículas, método para preparar nanopartículas e método para tratar terapeuticamente ou profilaticamente um indivíduo
BRPI0812446A2 (pt) Métodos para aperfeiçoamento de propriedades de proteína múltiplas
BRPI0922122A2 (pt) composições e métodos para tratamento de doença celíaca.
BR112012028530A2 (pt) composto, composição farmacêutica e seu processo de preparação e método para o tratamento de uma doença ou transtorno
BR112013023653A2 (pt) anticorpo biespecífico, método de preparação do anticorpo, e composição farmacêutica
BRPI0921317A2 (pt) composto, composição farmacêutica, e, método para tratar ou prevenir uma patologia relacionada com abeta em um mamífero
BR112014002616A2 (pt) método para detectar cãncer pancreático e reagente ou kit para detectar câncer pancreático
BRPI1004899A2 (pt) composto, composição farmacêutica, método para tratar uma doença ou distúrbio relacionado a pi3k em um indivíduo necessitando do mesmo, método para tratar uma doença mediada por mtor, método para tratar ambas as doenças mediadas por pi3k e hdac
BR112013026341A2 (pt) composto, composição farmacêutica, e, método para tratar, prevenir e/ou atrasar o início de uma doença ou patologia
BRPI0918178A2 (pt) anticorpos monoclonais para tratamento de câncer
BRPI0915382A2 (pt) composto, composição farmacêutica, e, método para tratar uma doença ou um distúrbio.
BR112013008957A2 (pt) composições e métodos para tratamento de doenças endócrinas, gastrointestinais ou autoimunes
BR112012004333A2 (pt) composto, composição farmacêutica, e, método para o tratamento ou a prevenção de uma doença ou um distúrbio.
BRPI0905761A2 (pt) Anticorpo humanizado ou fragmento de ligação ao mesmo, ácido nucléico isolado, vetor, célula hospedeira, método para produzir um anticorpo humanizado ou o fragmento de ligação ao mesmo, composição, método para tratar uma doença ou distúrbio mediado por vwf em um indivíduo, uso de um anticorpo humanizado ou fragmento de ligação do mesmo, método para administração do anticorpo humanizado ou fragmento de ligação do mesmo, artigo de fabricação e kit
BR112014010162A8 (pt) uso de composição, método para melhorar o reconhecimento e/ou tratar ou prevenir função de reconhecimento prejudicada em um indivíduo, e composição
BR112013029507A2 (pt) método para tratar uma doença ou um distúrbio
BR112013031712A2 (pt) composto, composição farmacêutica, métodos para preparar um composto e para o tratamento de um distúrbio ou uma doença.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/11/2012, OBSERVADAS AS CONDICOES LEGAIS.